aged ≥70 years at diagnosis with clinical stage I, node-negative, ER-positive breast cancer with negative margins who were to receive adjuvant tamoxifen randomized patients to receive lumpectomy with WBRT or lumpectomy alone. With a median follow up of
Search Results
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
Rodrigo Goncalves and Ron Bose
that the Onco type DX score predicted the likelihood of distant recurrence or breast cancer death when treated with hormonal therapy alone. 8 , 9 Archival samples from the NSABP B-14 trial, which tested the use of tamoxifen in patients with estrogen
Gayathri Nagaraj and Cynthia X. Ma
literature. Although the proportional risk reduction from adjuvant polychemotherapy was found to be independent of ER status and tamoxifen use in the Oxford overview, 3 the relative chemoresistance of ER+ disease has been demonstrated in the neoadjuvant
Lee S. Schwartzberg and Sarah L. Blair
receiving breast-conserving surgery without RT versus mastectomy, and 6 times higher for those receiving tamoxifen for less than 1 year compared with 5 years or more. 8 However, based on a prospective randomized clinical trial, carefully selected patients
Shaneli A. Fernando and Stephen B. Edge
adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic
Parijatham S. Thomas
(SERMs) and aromatase inhibitors (AIs) for the prevention of breast cancer. The Breast Cancer Prevention Trial (BCPT) evaluated 13,388 women aged ≥35 years with an elevated risk of breast cancer randomized to tamoxifen daily for 5 years or placebo
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
tumor was ER+ and/or PR+—tamoxifen. In the past decade, this approach was challenged by several findings. In 1998, a pivotal trial convincingly showed the clinical importance of tyrosine kinase signal transduction pathways by demonstrating that
John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner
Background Aromatase inhibitors (AIs), tamoxifen, and the sequential use of these agents are all standard options for adjuvant hormonal therapy (HT) for postmenopausal women with early-stage, estrogen receptor (ER)–positive breast cancer. At
Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia
had positive margins (3%); 31% were high grade. HR status was positive in 49%, but was missing in 42% of cases. Most women (83%) received RT for their initial DCIS; only 40% received AET. Of AET recipients, most (92%) took tamoxifen, 5% took an
Hannah Yoo and Anna Means
: IHC staining was performed on different precursor lesions of mouse pancreatic tissue (PanIN precursor: Ptf1aCre LSL-KrasG12D; IPMN precursor: Ptf1aCreERT LSL- KrasG12D Smad4fl/fltreated with tamoxifen) using markers of different IPMN subtypes and
